Vertex’s CASGEVY Marks Historic Milestone with First Commercial Patient Infusions, Paving the Way for 2025 Launches

CASGEVY Approval:
CASGEVY, a cell-based gene therapy developed by Vertex Pharmaceuticals, received FDA approval for the treatment of sickle cell disease and beta thalassemia in patients aged 12 years and older.

First Commercial Infusions:
The first commercial patients have received infusions of CASGEVY, marking a significant milestone in its launch.

Clinical Pipeline Progress:
Vertex reported strong progress in its clinical pipeline, including early revenue generation from CASGEVY and preparations for upcoming product launches like vanzacaftor for cystic fibrosis and suzetrigine for acute pain.

Long-Term Data:
Positive long-term data on CASGEVY were presented at the 2024 Annual European Hematology Association (EHA) Congress, demonstrating transformative, consistent, and durable benefits for patients with sickle cell disease and beta thalassemia.

2025 Launches:
Vertex is preparing for potential third and fourth product launches in early 2025, including the vanzacaftor triple therapy for cystic fibrosis and suzetrigine for moderate to severe acute pain.